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We investigated the safety and efficacy of liver-directed gene therapy using lentiviral vectors in a 
large animal model of hemophilia B, and evaluated the risk of insertional mutagenesis in tumor-
prone mouse models. We show that gene therapy using lentiviral vectors targeting expression of a 
canine factor IX transgene to hepatocytes was well-tolerated and provided stable long-term 
production of coagulation factor IX in dogs with hemophilia B. By exploiting three different 
mouse models designed to amplify the consequences of insertional mutagenesis, we show that no 
genotoxicity was detected with these lentiviral vectors. Our findings suggest that lentiviral vectors 
may be an attractive candidate for gene therapy targeted to the liver and may be useful for the 
treatment of hemophilia.
Introduction
Hemophilia is a monogenic X-linked disease caused by deficiency of coagulation factor VIII 
(hemophilia A) or factor IX (hemophilia B) (1). Bleeding is the hallmark of hemophilia, 
either spontaneous or post-traumatic, which can be fatal if left untreated. According to 
residual factor activity, hemophilia is classified as severe (<1%), moderate (1-5%) or mild 
(6-30%). Patients with moderate or mild hemophilia have occasional to rare spontaneous 
hemorrhages, thus rescuing factor activity at ≥1% of normal substantially benefits the 
clinical phenotype of severely affected patients (2).
Prophylactic or on-demand replacement therapy with recombinant products is the current 
standard of care for hemophilia in high-income countries and has improved the quality of 
life and life expectancy of patients with severe hemophilia (3). Nevertheless, this treatment 
has high costs and entails discomfort for patients and has the risk of inducing neutralizing 
anti-factor antibodies, which complicates further treatment (4). Moreover, about 80% of 
people affected by hemophilia live with no or unsatisfactory treatment, mainly in developing 
countries (5). Gene therapy could help to address these needs by establishing long-term 
endogenous production of the clotting factor at therapeutic levels after a single treatment (2, 
6, 7).
Recently, factor IX activity at 1-7% of normal has been reported long-term in adult patients 
with severe hemophilia B after administration of a single dose of an adeno-associated viral 
(AAV) vector targeting expression of human factor IX cDNA to hepatocytes (8). These 
results establish the therapeutic potential of liver-directed gene therapy in humans and offer 
the prospect of a definitive treatment for hemophilia. However, there are still important 
hurdles to overcome before this gene therapy can be applied to the majority of severely 
affected patients (9). In particular, pre-existing neutralizing antibodies to AAV following 
natural exposure to the wild-type virus may inhibit gene transfer with AAV vectors. In 
addition, AAV-specific cellular immune responses to the transduced hepatocytes may curtail 
long-term transgene expression and require transient immune suppression to allow clearance 
of AAV-derived antigens (8). HIV-derived lentiviral vectors may complement the therapeutic 
reach of AAV vectors because of the low prevalence of HIV infection in humans and the 
vector’s capacity to accommodate larger gene inserts. Moreover, the efficient integration of 
lentiviral vectors into the genome of target cells may eventually make these vectors better 
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suited for treatment of pediatric patients, in which hepatocyte turnover is high and episomal 
vectors may be progressively lost (10).
We have developed a lentiviral vector platform that achieves stable and robust transgene 
expression in the mouse liver and induces transgene-specific immune tolerance upon 
systemic administration (11–15). This lentiviral vector stringently targets transgene 
expression to hepatocytes through transcriptional and microRNA (miR)-mediated regulation. 
We and others have shown the efficacy of this vector in establishing correction of 
hemophilia B and A in mouse models and of hyperbilirubinemia in rats (12, 16, 17).
Although encouraging, these results were obtained in rodents and it is crucial to assess the 
feasibility and safety of scaling-up lentiviral gene therapy in large animal models. In 
addition, whereas liver gene transfer by lentiviral vectors appeared to be safe in treated mice, 
concerns remain regarding the risk of insertional mutagenesis. We and others recently 
reported safe and efficacious clinical testing of lentiviral vectors for ex vivo gene therapy 
with hematopoietic stem cells (18–20). The safe outcome of these trials to date supports the 
predictions about vector safety developed in our preclinical tumor-prone mouse models, 
where the consequences of insertional mutagenesis are amplified in a model species that 
otherwise limits detection of low incidence, vector-induced oncogenesis (21, 22).
Here, we investigated liver-directed gene therapy using lentiviral vectors in dogs with 
hemophilia B and tested the potential for genotoxicity in mouse models prone to develop 
hepatocellular carinoma.
Results
Lentiviral vectors efficiently transduce and regulate transgene expression in canine cells
We generated three lentiviral vectors with Self-Inactivating (SIN) Long Terminal Repeats 
(LTR) expressing cDNA transgenes for canine factor IX (cFIX) under the control of an 
internal synthetic hepatocyte-specific promoter (Enhanced Transthyretin, ET) and carrying 4 
tandem repeats of miR-142 target sequences (142T, Fig. 1A). The lentiviral vectors 
contained the wildtype, codon-usage optimized, or codon-usage optimized hyper-functional 
cFIX carrying the R338L mutation associated with human thrombophilia (cFIX, co-cFIX, 
co-cFIXR338L, respectively) (14, 23). All lentiviral vectors were pseudotyped with the 
vesicular stomatitis virus glycoprotein G (VSV-G).
We observed 2-fold to 5-fold reduction in lentiviral vector titer after incubation with pooled 
and individual dog sera, possibly mediated by complement (fig. S1A) (24). We selected for 
infusion those dogs whose serum showed the lowest neutralizing potential against lentiviral 
vectors. To verify lentiviral vector transduction and promoter activity in canine hepatocytes, 
we transduced primary human and canine hepatocytes ex vivo at increasing multiplicity of 
infection (MOI) with lentiviral vectors expressing GFP driven by the ubiquitously expressed 
phosphoglycerate kinase (PGK) promoter or the hepatocyte-specific Enhanced Transthyretin 
(ET) promoter. We observed high levels of transgene expression in hepatocytes of both 
species with both promoters (fig. S1B). We assessed miR expression in DH82 cells, a cell 
line derived from canine macrophages and found miR-142 to be expressed at high levels 
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(fig. S1C). We then transduced DH82 cells with reporter lentiviral vectors encoding GFP 
with or without 142T, and showed ≥100-fold downregulation of GFP expression (fig. S1D). 
These data indicate that the regulatory elements of our lentiviral vectors are functional in 
canine cells.
Intraportal lentiviral vector administration is well tolerated in dogs with hemophilia B
We produced three large-scale batches of lentiviral vectors according to a manufacturing 
process previously developed for clinical-grade lentiviral vectors (19, 20). Quality 
assessment of the vector batches (2009/D2, 2011/D13-15 and 2012/DG) is summarized in 
table S1. The process yielded 1.1-4.5x1010 transducing units (TU), corresponding to 864 - 
3,151 μg HIV Gag p24 equivalents (p24) of viral particles in 160-230 ml saline for infusion. 
Lentiviral vector infectivity was 0.63-4.4x104 transducting units (TU)/ng p24. The lentiviral 
vector batches had low endotoxin content, were sterile and free of replication-competent 
lentiviral vectors. The 3 batches differed for the cFIX transgene: they were either wildtype, 
co-cFIX, or co-cFIXR338L. Each lentiviral vector batch was infused into one male dog with 
hemophilia B by portal vein administration (Table 1).
The lentiviral vector infusion was well tolerated by the first dog (M57) except for a transient 
rise in body temperature (1° C above baseline). The second dog (O21) experienced acute 
hypotension during the infusion, attributed to an anaphylactoid reaction to an unknown 
component of the vector batch. This event was successfully managed by immediate 
administration of an antihistamine drug (Benadryl 1 mg/kg, i.v.) and corticosteroid 
(Dexamethasone 25 mg/kg i.v.). Lentiviral vector infusion was subsequently completed upon 
blood pressure recovery. We observed a transient rise in body temperature. Based on these 
events, the third dog (O59) was pre-treated with corticosteroid (Prednisone, 1 mg/kg oral) 
and anti-histamine drugs (Benadryl 1 mg/kg i.m., Famotidine 0.5 mg/kg i.m.) the day 
before, the morning before surgery, and just prior to vector infusion (Dexamethasone 0.2 
mg/kg i.v., Benadryl and Famotidine as above). Using this regimen, there was no change in 
blood pressure, the infusion was uneventful and body temperature did not increase.
In M57 and O21, serum concentrations of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) increased slightly above the normal range for the first few days 
post-infusion, indicating minor, self-limiting hepatocellular toxicity (Fig. 1B,C). In the third 
dog, both ALT and AST remained in the normal range throughout the follow-up, suggesting 
that anti-histamine and anti-inflammatory treatment prevented acute hepatotoxicity due to 
lentiviral vector infusion. In all three dogs, platelet counts fell slightly below the normal 
range for 2-3 days after lentiviral vector administration (Fig. 1D). This drop may be due to 
consumption at sites of surgical bleeding and to the large amount of fluid infused (vector 
vehicle plus normal canine plasma administered as a source of factor IX on the day of 
surgery and the following day), as also suggested by the concurrent transient drop in 
hematocrit (fig. S2A). Plasma concentrations of fibrinogen and thrombin/anti-thrombin 
complex (TAT) increased in the first few days after lentiviral vector administration, with the 
least evident changes in O59 (fig. S2B,C). The fibrin degradation product D-dimer increased 
only slightly above pre-treatment values in the first 2 dogs, and did not change in the third 
dog (fig. S2D). These data were consistent with the induction of an inflammatory response 
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and activation of the clotting system upon abdominal surgery and intraportal lentiviral vector 
administration. These responses were self-limiting and effectively prevented by a one-day 
anti-inflammatory pre-treatment in the third dog. Indeed, in all treated dogs, we found an 
increase in tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and IL-8 serum 
concentrations after lentiviral vector administration, which declined rapidly over the 
following hours or days (Fig. 1E-G). These increases were less pronounced in the dogs 
receiving anti-histamine and anti-inflammatory treatment. Other cytokines tested (IL-2, 
IL-4, IL-7, IL-10, IL-15, transforming growth factor-β, interferon-γ) were found not to be 
significantly different from control untreated animals (n=11). All of the other blood 
chemistry parameters tested and cell counts were in the normal range throughout the follow-
up, with minor sporadic fluctuations (tables S2-4)
We found very low concentrations of p24 in the serum at the first sampling, which was three 
hours after lentiviral vector administration (approximately 0.26% of the infused dose), 
indicating a rapid clearance of vector particles from the circulation (fig. S2E, F). We did not 
find detectable p24 in oral, nasal, lachrymal, genital and rectal swabs taken from day 1 to 8 
after lentiviral vector administration, except for a borderline signal in the nasal secretion of 
O21 at day 1 (table S5). Overall, these data suggest that administration of lentiviral vectors 
to dogs by intraportal delivery is well tolerated provided that anti-inflammatory and anti-
histamine treatment is given before infusion.
Lentiviral vector gene therapy provides stable improvement in clotting time and clinical 
benefit in dogs with hemophilia B
We measured the whole blood clotting time (WBCT), cFIX activity (by activated partial 
thromboplastin time, aPTT) and cFIX antigen in blood or plasma samples collected from 
treated dogs at routine intervals after lentiviral vector administration (Fig. 2A-C). The three 
dogs were followed up and were alive and well at 5, 2.5 and 1.75 years after lentiviral vector 
infusion for M57, O21 and O59, respectively. The WBCT was shortened and remained 
stable, albeit without reaching normal levels. The average WBCT over the follow-up time 
was approximately 20, 17 and 15.7 minutes for M57, O21, O59, respectively (Table 1). In 
M57, cFIX activity and antigen levels averaged 0.08% and 0.05% of normal, respectively 
(Table 1). Although the reconstituted activity was low, this dog experienced only 7 
spontaneous bleedings in the 5 years following gene therapy (out of 27 expected from the 
bleeding frequency in the colony), whereas it had experienced 6 bleedings in the 3 months 
before gene therapy (Fig. 2D). In dog O21, cFIX activity ranged between 0.3-1.7% and 
antigen levels were 0.2-0.9% of normal. This dog experienced only 2 bleedings over the last 
2.5 years. Since this dog received a 4-fold higher lentiviral vector dose and showed 
approximately 10-14 fold higher amounts of cFIX antigen and activity compared to dog 
M57, transgene codon-usage optimization may have increased cFIX expression by 3-fold as 
compared with the wildtype transgene, in line with our data obtained in mice (14). In dog 
O59, cFIX activity ranged between 0.6-1.9% but cFIX antigen levels was only 0.1-0.2% of 
normal (Table 1). Whereas the low antigen levels reflect the lower lentiviral vector dose 
administered compared to O21, the measured activity likely reflects the 5-10 fold increased 
activity conferred by the R338L mutation (14). This dog has not experienced any 
spontaneous bleeding to date. There is a marked difference in the monthly bleeding 
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frequency between treated and untreated dogs from the same colony (Fig. 2D, P < 0.0001; 
table S6). Thromboelastogram values were within or close to the normal range in all treated 
dogs, with a shorter time to clot in O21 and O59 dogs (table S7). Anti-factor IX inhibitory 
antibodies tested negative in all treated dogs (table S8). A liver biopsy was taken from M57 
and O21 at 16 and 12 months after lentiviral vector administration, respectively, and was 
scored normal by pathology (fig. S3). We found approximately 0.9 and 2.4 lentiviral vector 
DNA copies for every 1,000 diploid genomes, respectively (fig. S4). This finding confirms 
the presence of lentiviral vector in the dog liver in amounts consistent with the measured 
factor IX output. We did not find detectable lentiviral vector DNA in blood and sperm 
samples obtained from the treated dogs (fig. S4). These data show the long-term persistence 
of lentiviral vector-transduced cells in canine liver, stable reconstitution of factor IX activity 
up to 1% of normal and amelioration of the clinical phenotype in 3 treated dogs affected by 
hemophilia B.
Treated mice did not show evidence of genotoxicity after lentiviral vector integration in 
liver
The normal blood chemistry and the stability of factor IX expression in the long-term follow 
up of the treated dogs suggests a low risk for the development of neoplasia from transduced 
hepatocytes. To better investigate the risk of oncogenesis, we turned to mice and analyzed 
the safety of lentiviral integration into the liver in multiple settings of escalating stringency. 
In our prior studies of lentiviral vector gene therapy in mice with hemophilia B, we did not 
observe macroscopic liver lesions at necropsy in the treated mice (12, 14, 15). Here, we 
analyzed the integration site distribution in the liver of treated mice and scored for the 
potential enrichment of integration sites at specific genomic loci over time. Such analyses 
could reveal a selective growth advantage conferred on hepatocytes by lentiviral vector 
integration close to cancer genes before the development of overt neoplasia.
Twenty-seven adult mice with hemophilia B were administered 2.5-5x1010 transducing 
units/kg therapeutic lentiviral vector (which carries Self-Inactivating long terminal repeats 
and an internal ET promoter, SIN.ET, expressing human or canine wildtype factor IX, see 
also Fig. 1A) in 5 different experiments (table S9). As expected, plasma factor IX was at 
10-15% of normal levels and did not significantly change between sampling performed 
“early” (<3 months) or “late” (6-12 months) after lentiviral vector administration (Fig. 3A) 
(12, 14). Nine mice were euthanized “early” and 18 were euthanized “late” to measure 
lentiviral vector content and integration site distribution in the liver. There was no significant 
difference in the average vector copies per diploid genome (Vector Copy Number, VCN) 
between the early and late time points (Fig. 3B). We then deep sequenced integration sites 
by linear-amplification mediated-PCR followed by 454 pyrosequencing or Illumina 
sequencing and mapped a total of 17,008 unique integration sites onto the murine genome 
(table S9-10). We applied standard criteria to identify genomic regions recurrently hit by 
lentiviral vector integrations with a frequency significantly higher than random, and defined 
them as Common Insertion Sites (CIS) (25). We identified 270 and 77 CIS in the datasets of 
integration sites retrieved from early or late euthanized mice, respectively, each CIS being 
identified by the most targeted gene within the genomic region (table S11). The higher 
number of CIS from the “early” integration site dataset is likely to be the consequence of the 
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higher number of integration sites retrieved. Nearly half of the “late” CIS were also found 
among the “early” dataset (Fig. 3C), suggesting that they are unlikely to be the result of in 
vivo selection of clones carrying integration at those genes. In contrast, lentiviral vector CIS 
often result from intrinsic biases of viral integration that preferentially target gene-dense 
genomic regions (26). We thus used the genome-wide Grubb’s test for outliers to exclude all 
the CIS occurring within a larger genomic cluster of lentiviral vector integrations, likely 
representing integration biases, as previously described (19, 20). None of the “late” CIS 
passed the Grubb’s test, except for the Sfi1 gene, which was also found among the “early” 
CIS. Overall, this analysis did not find evidence of in vivo selection of mouse hepatocytes 
carrying SIN.ET integrations.
No evidence of genotoxicity after SIN lentiviral vector administration to tumor-prone mice
Mice can only be administered a limited dose of vector and followed-up for a short time 
given their short lifespan compared to humans. For this reason, insertions leading to gain or 
loss of function in cancer genes that have a delayed effect on hepatocyte proliferation and/or 
selection may have escaped detection in the previous analysis (Figure 3). In order to increase 
the sensitivity of our analysis, we administered the SIN.ET lentiviral vector to newborn 
tumor-prone mice or wildtype mice given a tumor-promoting regimen (27). We used a 
previously described genotoxic lentiviral vector carrying transcriptionally active Long 
Terminal Repeats containing the ET promoter as a positive control for genotoxicity (ET.LTR 
lentiviral vector; Fig. 4A). Matched doses of ET.LTR or SIN.ET lentiviral vector (2.5x1010 
transducing units/kg) were administered to newborn Cdkn2a-/-Ifnar1-/- mice or newborn 
wildtype mice that were then given a regimen of CCl4; 125 new experimental mice and 29 
historical controls (27) were analyzed (table S12). Cdkn2a-/-Ifnar1-/- mice were euthanized if 
they displayed signs of illness or at 30 weeks of age. Wildtype mice given the CCl4 regimen 
were euthanized at 1 year of age. By visual inspection at necropsy and histopathological 
analysis of serial liver sections from multiple lobes, we detected two microscopic 
hepatocellular carcinomas (HCC) in 62 tumor-prone or CCl4-treated wildtype mice 
administered SIN.ET, an incidence overlapping with that observed in nontransduced mice. 
On the contrary, ET.LTR induced a significantly higher incidence of HCC (P = 0.0007 for 
Cdkn2a-/-Ifnar1-/-, P < 0.0001 for CCl4-treated wildtype mice), most of which were visible 
at necropsy (Fig. 4B-C and fig. S5A-D). We measured the vector copy number in non-
tumoral mouse liver and in the HCCs collected from the experimental groups at the end of 
the experiment, and from 4 cohorts of mice (Cdkn2a-/-Ifnar1-/- or wildtype) euthanized 2 
weeks after neonatal administration of SIN.ET or ET.LTR lentiviral vectors. The SIN.ET 
and ET.LTR vector copy number were comparable in mice euthanized at 2 weeks of age, 
indicating comparable in vivo transduction. However, the ET.LTR vector copy number was 
higher in livers harvested at the end of the experiment and showed an even greater increase 
in HCCs, indicating expansion of transduced hepatocytes (P = 0.0394, Fig. 4D, E). This 
increased vector copy number over time was not observed in SIN.ET-treated mice. 
Moreover, we did not detect any significant change in circulating factor IX over time in 
either Cdkn2a-/-Ifnar1-/- mice or wildtype mice transduced with SIN.ET, confirming the 
stability of gene transfer after administration to neonatal mice (fig. S5E, F). These data 
suggest that there was not transformation or expansion of SIN.ET-transduced hepatocytes 
even in sensitive mouse models administered lentiviral vectors as neonates.
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We then retrieved lentiviral vector integrations from 83 liver samples (by linear-
amplification mediated-PCR and 454 pyrosequencing) and identified 9,615 unique 
integration sites (table S13). We identified 60 and 12 CIS in the datasets of integration sites 
from SIN.ET- and ET.LTR-treated mice, respectively (table S13). There was almost no 
overlap between the SIN.ET and ET.LTR CIS (Fig. 5A), and the latter CIS were also 
different from the CIS identified in SIN.ET-transduced mice with hemophilia reported in 
Figure 3C (fig. S6A). Moreover, when we applied the Grubb’s test, the only significant CIS 
of SIN.ET was Sfi1, already found in the integration sites of mice with hemophilia 
euthanized early and late after lentiviral vector administration, and thus most likely due to an 
intrinsic lentiviral vector integration bias (table S14). Conversely, 5 of the ET.LTR CIS 
passed the Grubb’s test for outliers (table S14), among which were found the genes Braf, 
Rtl1 and Fign and three previously validated liver oncogenes (27). ET.LTR integration sites 
within these CIS were clustered in narrow regions and almost always in the same orientation 
of transcription as the targeted gene, consistent with a previously described mechanism of 
insertional mutagenesis. This mechanism involves transcription from the inserted active LTR 
and splicing into the oncogene, leading to up-regulation of expression of a truncated or full-
length oncogenic transcript and in vivo expansion of cells harboring that integration site 
(Fig. 5B, fig. S6B, C) (27). These data confirm the genotoxic features of the positive control 
lentiviral vector and the sensitivity of the mice to insertional oncogenesis. In contrast, 
integration sites for SIN.ET CIS had a lower integration density without orientation bias (Fig 
5C, fig. S6D). Additionally, we found that the power and density of SIN.ET CIS, two 
measures of the extent of enrichment over random occurrence, were significantly lower (P = 
0.0128, P < 0.0001 respectively) as compared to those of ET.LTR (Fig. 5D and figure S6E). 
We also compared the relative sequence counts of all the integration sites in a CIS as a 
surrogate readout of the relative abundance of cell clones harboring integration at that CIS 
within sampled liver tissues of that experimental group (Fig. 5E). The relative sequence 
counts of SIN.ET CIS were significantly lower than those of ET.LTR CIS retrieved from 
non-tumoral or tumoral samples (Fig. 5E, P < 0.0001). These data further indicate that 
SIN.ET CIS were not the result of in vivo clonal selection or expansion. Accordingly, the 
analysis of molecular pathways enriched in the CIS datasets showed that ET.LTR-targeted 
genes frequently act in pathways associated with cancer and transformation, whereas 
SIN.ET-targeted genes did not (fig. S6F). Overall, we did not detect evidence of SIN.ET-
induced genotoxicity, even after investigation of early molecular readouts of transformation 
in highly permissive tumor-prone mice or mice in which tumors were chemically promoted.
Discussion
Here, we show that lentiviral vector-mediated gene therapy in the liver of dogs with 
hemophilia B is feasible and provides stable long-term factor IX activity up to 1% of normal 
activity with therapeutic benefit. The treatment was associated with manageable self-limiting 
acute toxicity without any detectable long-term toxicity or development of anti-transgene 
immune responses.
We produced 3 large-scale batches of lentiviral vectors for in vivo administration and 
analyzed them using a panel of tests for identity, potency and purity, according to methods 
and specifications previously used for clinical trials (20). Upon portal vein administration of 
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these lentiviral vectors carrying a factor IX transgene to dogs with hemophilia B, we 
observed mild transient fever and hepatocellular toxicity accompanied by a transient rise in 
circulating TNF-α, IL-6, IL-8, fibrinogen and thrombin/anti-thrombin complex. This acute 
inflammatory response may be a consequence of abdominal surgery and type-I interferon 
release by hepatosplenic plasmacytoid dendritic cells, triggered by nucleic acids 
contaminating or associated with the infused vector particles, as has been observed in 
previous mouse studies (28). This response was alleviated in one dog pretreated with anti-
inflammatory and anti-histamine drugs one day before lentiviral vector infusion, a mild 
regimen that could also be translated to the clinical setting. In one dog, we observed a 
hypotensive anaphylactoid reaction to an unknown component during lentiviral vector 
infusion. Given that dogs with hemophilia B receive frequent plasma transfusions in 
response to spontaneous bleedings, they may be pre-sensitized to developing allergic 
reactions.
Our prior studies in mice with hemophilia B indicated that an optimal lentiviral vector dose 
to achieve >5% of normal factor IX activity is 2.5x1010 transducing units/kg. According to 
manufacturing capacity at the beginning of this study and precautions dictated by the testing 
of lentiviral vectors in large animals, we administered a 45-fold lower dose, 5.7x108 
transducing units/kg, to the first dog (M57). Given that canine factor IX activity approached 
0.1% of normal, this outcome suggests that predictions based on the dose-response in the 
mouse are reliable in the canine model. Through improvements in large-scale vector 
production and transgene codon-usage optimization, we could administer a 4-fold higher 
dose to a second dog (O21). This dog achieved about 1% of normal canine factor IX activity, 
which was more than 10-fold higher than that for the first dog. This can be explained by the 
2-3 fold gain in potency of the codon-optimized canine factor IX as had previously been 
observed in mice (14). By exploiting the Padua mutation that confers 7-fold higher activity 
on activated factor IX (14, 23), we could reconstitute 1% of normal canine factor IX activity 
in a third dog, even though it was administered a 2-fold lower dose compared to dog O21. 
Overall, these results show that by delivering a codon-optimized and hyper-functional factor 
IX transgene one can reduce the effective lentiviral vector dose by more than 1 log. 
Importantly, all dogs experienced a long-lasting therapeutic benefit from the single 
treatment, as shown by a marked decrease in spontaneous bleedings recorded throughout the 
follow-up period of several years. Moreover, the treatment did not induce anti-factor IX 
inhibitory antibodies consistent with the observed stable long-term factor IX activity in 
plasma. However, it should be noted that the dogs treated in this study, although totally 
devoid of circulating factor IX (29), do bear a missense mutation in their F9 gene and thus 
are not prone to developing anti-factor IX antibodies.
There are a number of limitations to our study. The main limitation is the small number of 
dogs treated, each treated with a different transgene and vector dose. In addition relatively 
low doses of lentiviral vector were administered, giving rise to transgene expression at the 
threshold of therapeutic activity. Thus, further dose-escalating studies in dogs as well as in 
non-human primates are warranted to investigate the potential occurrence of dose-limiting 
acute toxicity and the lentiviral vector stability in blood and biodistribution in multiple 
tissues. These further studies will be crucial to establish the safety of in vivo administration 
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of lentiviral vectors to large animal models and to establish that there is no immune response 
to the transgene.
If we extrapolate the observed dose-response in dogs to humans, the current lentiviral vector 
manufacturing capacity (20) could support the treatment of adult patients with hemophilia, 
provided that a hyper-functional factor IX transgene is used. The manufacturing of lentiviral 
vectors for clinical use should become less onerous through further improvements in 
procedures and scale-up and the availability of stable packaging cell lines.
The occurrence of vector-induced oncogenesis in hematopoietic stem cell gene therapy trials 
based on gamma-retroviral vectors necessitates stringent preclinical assessment of potential 
vector genotoxicity (30–33). This caution also applies to liver gene therapy as hepatocytes 
are susceptible to insertional mutagenesis (27, 34–37). Accumulating evidence from non-
clinical studies and recent clinical trials supports the view that lentiviral vectors entail a 
lower genotoxic risk compared to gamma-retroviral vectors (19, 21, 22, 38). Given that most 
studies of vector-induced genotoxicity have focused on hematopoietic stem and progenitor 
cells, we undertook a preclinical analysis of lentiviral vector-induced genotoxicity in the 
mouse liver. We did not find evidence of genotoxicity of our therapeutic lentiviral vectors in 
mice with hemophilia B and in two ad hoc mouse models with enhanced sensitivity to 
hepatocellular carcinogenesis (>100 mice and >9,000 integration sites analyzed).
The distribution of lentiviral vector integrations in liver DNA of mice with hemophilia 
showed that deviations from random were already evident early after gene therapy, thus most 
likely representing intrinsic integration biases of the vector and not the outcome of in vivo 
selection. This contention was supported by the substantial overlap between the CIS 
identified in “early” and “late” liver harvests and the lack of new CIS that passed the 
Grubb’s test for outliers in the “late” dataset. Note that our sampling and depth of analysis 
were not designed to attain saturation of CIS, thus we did not expect full overlap between 
the early and late CIS.
The low genotoxicity of the SIN.ET lentiviral vector design was further demonstrated by 
administration to tumor-prone mice where this vector did not increase the spontaneous 
occurrence of HCC. This was at variance with an aptly designed genotoxic lentiviral vector 
serving as a positive control. Lentiviral vectors were administered to newborn mice, thus 
increasing the likelihood that proliferating hepatocytes would accumulate additional 
mutations complementing an eventual oncogenic lentiviral insertion resulting in the 
induction of hepatocyte transformation. The observation that SIN.ET CIS have lower 
integration power, integration density and representation in the whole dataset compared to 
ET.LTR CIS indicates that SIN.ET integration sites are not subject to the same process of in 
vivo selection as ET.LTR integration sites. We found 3 previously validated liver oncogenes 
(Braf, Fign and Rtl1) as significant CIS after Grubb’s test in the ET.LTR dataset. Moreover, 
for some oncogenes such as Fign, we could observe clustering of ET.LTR integration sites in 
a significant CIS even in non-tumoral tissues (see Fig. 5B), indicating that our experimental 
design could detect the occurrence of clonal selection due to an oncogenic vector even 
before overt neoplasia. Therefore, it is unlikely that the lack of evidence for in vivo selection 
of SIN.ET insertions was due to a limited sensitivity of our assay. Rather, our studies did not 
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uncover any biological or molecular evidence of SIN.ET-induced genotoxicity even in the 
“worst-case scenario” of transduction of newborn tumor-prone mice.
In conclusion, our study positions liver-directed lentiviral gene therapy for further pre-
clinical development. Lentiviral vectors may complement other available vectors to address 
some of the outstanding challenges posed by liver gene therapy for the treatment of 
hemophilia and conceivably other diseases.
Materials and methods
Study design
Dog studies were necessarily limited in sample size for feasibility and ethical reasons. 
Sample size of mouse studies was chosen according to the previously observed tumor 
incidence in the positive control group (27). No sample or animal administered the intended 
dose was excluded from the analysis. Mice were randomly attributed to each experimental 
group. Investigators involved in histopathology analysis and initial integration sites mapping 
were blinded. Investigators performing mouse handling, sampling, euthanasia and raw data 
analysis were not blinded.
Large-scale lentiviral vector production
Large-scale lentiviral vector production for dog studies was outsourced to MolMed S.p.A. or 
Genethon. The vector batches were produced by using a large-scale validated process (19, 
20) and following pre-GMP guidelines. Briefly, lentiviral vectors are produced by transient 4 
plasmid transfection of 293T cells in 10-tray cell factories by calcium phosphate 
precipitation. Twenty-four hours after removal of the transfection medium, the cell 
supernatant is harvested and stored at 4°C. The culture medium is replaced and after further 
24 hours a second harvest is performed. The medium collected from the two harvests is 
pooled and filtered through 5/0.45 μm filters to discard cell debris. The downstream 
purification process includes a benzonase treatment overnight at 4°C, followed by a 
DiEthylAmino Anion Exchange (DEAE) chromatography step, concentration and gel 
filtration in PBS or PBS 5% dimethyl sulfoxide (DMSO). The resulting lentiviral vector 
preparation undergoes 0.2 or 0.45 μm filtration and aseptic filling. The purified vector 
preparation is stored at –80°C.
Dog experiments
Hemophilia B dogs (carrying a E379G single amino-acid substitution in the factor IX 
protein) were maintained at the Francis Owen Blood Research Laboratory, which provides 
for breeding, whelping, housing, treating and performing the experiments in the dogs on site. 
Complete blood counts and platelet counts were performed on EDTA-anti coagulated blood 
with a cell counter (Heska) calibrated for canine cells. Serum liver enzymes were performed 
by Antech Diagnostics, a commercial veterinarian diagnostic laboratory.
Mouse experiments
Founder C57BL/6 F9 KO mice were kindly obtained from the laboratory of Dr. Inder Verma 
at the Salk Institute (39). Cdkn2a-/-Ifnar1-/- mice were generated to couple the sensitivity to 
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genotoxic mutations conferred by the Cdkn2a deficiency (21, 22) to the increased 
permissiveness to liver gene transfer by lentiviral vectors conferred by the Ifnar1 deficiency 
(28). Additionally, this non-inflammatory tumor-prone mouse model has a clinical 
relevance, since CDKN2A and its targets – pRB and p53 - are frequently inactivated or 
silenced in HCC (40). Cdkn2a-/- (C57BL6/J) mice were obtained from NCI-Frederick 
MMHCC Repository, while Ifnar1-/- (129SVEV) mice were obtained from B&K Universal 
Limited. Wildtype C57BL/6 mice were purchased by Charles River. Eight-week old 
wildtype mice transduced or not with ET.LTR at neonatal stage, were administered CCl4 1 
mg/kg twice weekly for 6 weeks in a 10% mineral oil solution (Sigma). CCl4 administration 
results in waves of hepatocytes necrosis and regeneration that cause liver damage (41). Both 
mouse models were previously described (27).
All the mice were maintained in specific-pathogen free conditions. Vector administration 
was carried out by tail-vein injections in adult (7-10 weeks old) mice and by temporal vein 
injection in newborns (1-2 days old). Mice were bled from the retro-orbital plexus using 
capillary tubes and blood was collected into 0.38% sodium citrate buffer, pH 7.4. Mice were 
anesthetized with tribromoethanol (Avertin) and euthanized by CO2 inhalation. All animal 
procedures were performed according to protocols approved by the Institutional Animal 
Care and Use Committee. At necropsy we collected masses in the liver parenchyma as well 
as non-tumoral liver for microscopic and molecular analyses.
Statistical analysis
Statistical analyses were performed upon consulting with professional statisticians. When 
data were %, Log Odds were calculated to perform tests assuming normal distribution (42). 
Standard statistical tests were performed using Student’s t test (2 experimental groups) or 
ANOVA with Bonferroni multiple comparison’s post-test (>2 experimental groups) at 
α=0.05 level of confidence.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Short One Sentence Summary
Lentiviral vector-mediated gene therapy targeted to hepatocytes provides stable 
reconstitution of clotting activity in dogs with hemophilia B.
Long One Sentence Summary
Gene therapy with lentiviral vectors targeting transgene expression to hepatocytes 
provides stable reconstitution of clotting activity in dogs with hemophilia B and does not 
show genotoxicity in tumor-prone mice.
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Advances in gene therapy for hemophilia
Hemophilia is an inherited bleeding disorder caused by deficiency in a blood clotting 
factor. The current treatment requires lifelong intravenous administration of the missing 
clotting factor every few days, a costly and demanding regimen for the patients. Gene 
therapy can provide a single-shot treatment option by replacing a functional gene in the 
liver cells that naturally produce the factor. Here we report a study of the efficacy and 
safety of liver-directed in vivo gene therapy in large and small animal models using 
lentiviral vectors. The strategy described here promises to represent a new gene therapy 
option, which may complement other available vectors for hemophilia and conceivably 
other diseases.
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Figure 1. Intraportal administration of lentiviral vectors to dogs with hemophilia B.
(A) Schematic representation of the third-generation Self Inactivating (SIN) lentiviral 
vectors (proviral form) used in this work [U3 del: deletion of the promoter/enhancer of the 
HIV Long Terminal Repeats (LTR) (43)]. SD: splicing donor site. SA: splicing acceptor site. 
ψ: packaging signal. Wpre*: mutated woodchuck hepatitis virus post-transcriptional 
regulatory element (44). 142T: miR-142 target sequence made of 4 tandem copies of a 
sequence perfectly complementary to miR-142. Hepatocyte-specific Enhanced Transthyretin 
(ET) promoter composed of synthetic hepatocyte-specific enhancers and transthyretin 
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promoter (45). The wildtype, codon-usage optimized, and codon-usage optimized and 
hyper-functional cDNAs of canine factor IX (cFIX, co-cFIX, co-cFIXR338L) were used as 
transgenes (14). Serum concentrations of alanine aminotransferase, ALT (B) and aspartate 
aminotransferase, AST (C), platelet counts (D), and serum concentrations of TNF-α (E), 
IL-6 (F) and IL-8 (G) were measured in blood samples collected at the indicated time points 
after lentiviral vector administration to dogs M57 (grey line), O21 (green line), and O59 
(blue line). Baseline values are shown as “time 0”. (B-D) The normal range is shown 
(dashed lines). (E-G) The mean ± standard deviation (grey area) and range (dashed lines) of 
the serum concentrations of each cytokine measured in samples collected from 11 control 
untreated dogs are shown. Note that the lowest range for TNF-α and IL-6 is 0. Dog O59 was 
administered corticosteroids and anti-histamine drugs before lentiviral vector infusion to 
reduce inflammation.
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Figure 2. Lentiviral vector-mediated gene therapy targeted to liver provides stable improvement 
in clotting time in dogs with hemophilia B.
Whole blood clotting time, WBCT (A) measured in blood samples, canine factor IX activity 
(cFIX) (B) and cFIX antigen (C) measured by activated partial thromboplastin time, aPTT 
(B) or ELISA (C) in plasma samples collected at the indicated times after lentiviral vector 
administration from dogs M57 (grey line), O21 (green line), O59 (blue line) 0. The colored 
vertical lines indicate 27 days after the last normal plasma transfusion of the dogs at which 
time exogenous canine factor IX had been washed-out. (D) Frequency of spontaneous 
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bleedings (bleeding events/month of observation) in the treated dogs after gene therapy. For 
M57, the frequency of spontaneous bleeding before gene therapy is shown. The mean ± SD 
bleeding frequency of 10 untreated dogs with hemophilia B in the colony is shown (black 
bar) (46). P < 0.0001 (2-sample test for equality of proportions; see also table S6).
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Fig. 3. No evidence of genotoxicity after lentiviral vector integration into liver of mice.
(A) Factor IX antigen measured by ELISA in the plasma collected from mice “early” (<3 
months) or “later” (6-12 months) after lentiviral vector administration. P = 0.391, Student’s t 
test. (B) Vector copy number (VCN) in liver DNA collected from mice euthanized early or 
later after lentiviral vector administration. P = 0.806, Student’s t test. (A, B) Data are mean
±standard error of the mean (SEM). (C) Venn diagram representing Common Insertion Sites 
(CIS) identified in liver DNA of mice euthanized early or later after lentiviral vector 
administration. The overlap is calculated considering the gene associated with each CIS; the 
number of CIS that passed the Grubb’s test is shown along with the gene name. The number 
of samples analyzed and integration sites retrieved are indicated for the two data sets.
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Figure 4. SIN.ET lentiviral vectors do not induce hepatocellular carcinoma in tumor-prone mice.
(A) Experimental outline of the in vivo biosafety study in mice. (Left) Schematic 
representations of the lentiviral vectors used U3 del: deletion of the promoter/enhancer of 
the HIV Long Terminal Repeats (LTR) (43). SD: splicing donor site. SA: splicing acceptor 
site. ψ: packaging signal. Wpre*: mutated woodchuck hepatitis virus post-transcriptional 
regulatory element (44). 142T: miR-142 target sequence made of 4 tandem copies of a 
sequence perfectly complementary to miR-142. Hepatocyte-specific Enhanced Transthyretin 
(ET) promoter composed of synthetic hepatocyte-specific enhancers and transthyretin 
promoter (45). Either SIN.ET (gene therapy lentiviral vector with Self Inactivating Long 
Terminal Repeats and an internal Enhanced Transthyretin promoter) or ET.LTR (oncogenic 
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lentiviral vector with transcriptionally active Long Terminal Repeats containing the 
Enhanced Transthyretin promoter) were administered at matched doses to newborn 
Cdkn2a-/-Ifnar1-/- tumor-prone mice or wildtype mice resulting in four experimental groups. 
Wildtype mice then were given a CCl4-based tumor promoting regimen. Mice were 
euthanized at the indicated time points or earlier if sick. Necropsy was performed and 
samples were collected for DNA extraction (for determination of vector copy number and 
the retrieval of integration sites ) and for histopathology analysis. (B, C) Shown is the 
incidence of hepatocellular carcinoma (HCC) in Cdkn2a-/-Ifnar1-/- mice (B) or wildtype 
mice (C) transduced with the two different lentiviral vectors (SIN.ET or ET.LTR) or 
untransduced (UNT). Untransduced mice include historical controls (n=20 Cdkn2a-/-Ifnar1-/- 
and n=9 wildtype mice) (27). P values were calculated by two-tailed Fisher’s exact test. 
Numbers on the histograms indicate the number of mice that developed HCC. (D, E) Vector 
copy number in liver DNA from Cdkn2a-/-Ifnar1-/- mice (D) or wildtype mice (E) collected 
two weeks after lentiviral vector administration (early) or at necropsy (late). Data are mean
±SEM. P values were calculated by One-Way ANOVA and Bonferroni’s multiple correction 
test. All vector copy numbers were measured in non-tumoral liver tissue except for ET.LTR-
induced HCCs.
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Fig. 5. Integration sites analysis does not reveal genotoxicity of SIN.ET lentiviral vectors in 
tumor-prone mice.
(A) Venn diagram representing Common Insertion Sites (CIS) identified in liver DNA of 
SIN.ET-transduced and ET.LTR-transduced mice. The overlap is calculated considering the 
gene associated with each CIS. The number of CIS that passed the Grubb’s test is shown 
with the gene name (red). The number of samples analyzed and the total number of 
integration sites are indicated for the two data sets. (B, C) Schematic drawing of two 
representative CIS of ET.LTR (B) and SIN.ET (C) lentiviral vectors. Each colored bar 
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represents an integration site (red: from ET.LTR-induced HCCs; orange: from non-tumoral 
liver of mice transduced with ET.LTR; black: from liver of mice transduced with SIN.ET). 
Colored arrows indicate the orientation of the integration site. The gene within the region is 
represented below, with black boxes indicating exons and arrows indicating the transcription 
orientation. The span of the outlined genomic region is indicated on top. (D) Common 
insertion sites (CIS) power, calculated as the number of different integration sites targeting 
each CIS. (E) CIS representation, calculated as % of sequencing reads from all integration 
sites comprised within a CIS over the total number of reads within an experimental data set. 
(D, E) Data are mean±SEM. P values were calculated by One-Way ANOVA and 
Bonferroni’s multiple correction test. For all the analyses, integration sites from the two 
mouse models were merged.
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Table 1
Gene therapy dose-response in treated dogs with hemophilia B.
DOG M57 (Hemil) O21 (Valentine) O59 (Enzo)
Age at treatment 8 months 21 months 21 months
Weight at treatment 20 kg 22 kg 18 kg
Transgene wt cFIX co-cFIX co-cFIXR338L
TU/kg 5.7x108 2.3x109 1.1x109
μg p24/kg 44 47 174
FU (days) 1831 900 637


















The table shows the age and weight at treatment of three dogs with hemophilia B (M57, O21, O59), the infused dose of lentiviral vector 
(transducing units, TU and physical particles) per weight, the follow up (FU) time in days, the Whole Blood Clotting Time (WBCT) in minutes 
(min), and the canine factor IX (cFIX) activity (determined by activated partial thromboplastin time, aPTT). Also shown are the cFIX antigen 
(determined by ELISA), the type of transgene contained in the infused lentiviral vector: wildtype (wt), codon-usage optimized, or codon-usage 
optimized hyperfunctional cFIX cDNAs (cFIX, co-cFIX, co-cFIXR338L; see also Fig. 1). When possible, results are presented as mean±standard 
error of the mean of values over time (range of determined values is also shown). The values of WBCT, cFIX activity and antigen are considered 
valid only if measured 27 days after the last canine plasma transfusion (to ensure washout of exogenous cFIX).
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